← Leaderboards
Dongsheng Duan
University Of Florida
$17,353,422
Attributed
$18,688,371
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,688,371 · 12
By mechanism
R01$16,727,861 · 6
R21$1,860,902 · 5
R56$99,608 · 1
Top collaborators
- Roland W. Herzog3 shared
- Arun Srivastava2 shared
Most similar at University Of Florida
Same institution · by research overlap
- Terence E Ryan$4,690,955
- Barry J. Byrne$9,633,932
- Chelsey Savannah Simmons$1,835,445
- Carol C Gregorio$19,713,203
- Lei Zhou$4,119,528
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorGenesDependovirusMuscleAdeno-Associated Viral VectorMyopathyMediatingDystrophinCanis FamiliarisGene TransferMuscular DystrophiesAnimal ModelAffectFutureProteinsLeadMouse ModelFoundationsTreatment EfficacyDuchenne Muscular DystrophyLengthPhysiologicalProtocols Documentation
Grant awards (43)
Mechanism of immune response to muscle-directed AAV gene transfer$759,377
R01 · FY2025 · AI
Whole body single AAV microgene in canine DMD$598,651
R01 · FY2025 · NS · contact PI
CRISPR editing therapy for Duchenne muscular dystrophy$556,979
R01 · FY2025 · NS · contact PI
Mechanism of immune response to muscle-directed AAV gene transfer$759,377
R01 · FY2024 · AI
CRISPR editing therapy for Duchenne muscular dystrophy$552,403
R01 · FY2024 · NS · contact PI
Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies$163,754
R21 · FY2024 · AR
Mechanism of immune response to muscle-directed AAV gene transfer$774,002
R01 · FY2023 · AI
CRISPR editing therapy for Duchenne muscular dystrophy$530,218
R01 · FY2023 · NS · contact PI
Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies$213,389
R21 · FY2023 · AR
CRISPR therapy in the canine DMD model$99,608
R56 · FY2022 · AR · contact PI
Treatment of Duchenne Muscular Dystrophy with the Muscle Calcium Pump$616,487
R01 · FY2020 · AR · contact PI
Treatment of Duchenne Muscular Dystrophy with the Muscle Calcium Pump$616,487
R01 · FY2019 · AR · contact PI
Whole body single AAV microgene therapy in canine DMD$600,331
R01 · FY2019 · NS · contact PI
Treatment of Duchenne Muscular Dystrophy with the Muscle Calcium Pump$616,487
R01 · FY2018 · AR · contact PI
Whole body single AAV microgene therapy in canine DMD$600,331
R01 · FY2018 · NS · contact PI
Treatment of Duchenne Muscular Dystrophy with the Muscle Calcium Pump$622,685
R01 · FY2017 · AR · contact PI
Whole body single AAV microgene therapy in canine DMD$600,331
R01 · FY2017 · NS · contact PI
R16/17-Independent nNOS Anchoring Mechanism$160,713
R21 · FY2017 · AR · contact PI
Treatment of Duchenne Muscular Dystrophy with the Muscle Calcium Pump$623,664
R01 · FY2016 · AR · contact PI
Whole body single AAV microgene therapy in canine DMD$600,331
R01 · FY2016 · NS · contact PI
R16/17-Independent nNOS Anchoring Mechanism$194,516
R21 · FY2016 · AR · contact PI
Whole body single AAV microgene therapy in canine DMD$600,331
R01 · FY2015 · NS · contact PI
Duchenne Cardiomyopathy Gene Therapy$479,471
R01 · FY2013 · HL · contact PI
Duchenne Cardiomyopathy Gene Therapy$509,872
R01 · FY2012 · HL · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$391,167
R01 · FY2012 · AR · contact PI
Duchenne Cardiomyopathy Gene Therapy$516,261
R01 · FY2011 · HL · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$391,167
R01 · FY2011 · AR · contact PI
Duchenne Cardiomyopathy Gene Therapy$520,740
R01 · FY2010 · HL · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$395,419
R01 · FY2010 · AR · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$521,831
R01 · FY2009 · AR · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$423,864
R01 · FY2009 · AR · contact PI
Exploring systemic AAV gene delivery in the dystrophic dog$196,423
R21 · FY2009 · AR · contact PI
Expressing full-length dystrophin with AAV$196,219
R21 · FY2009 · NS · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$438,213
R01 · FY2008 · AR · contact PI
Novel hybrid AAV vectors for cystic fibrosis gene therapy$214,736
R21 · FY2008 · DK · contact PI
Exploring systemic AAV gene delivery in the dystrophic dog$175,887
R21 · FY2008 · AR · contact PI
Expressing full-length dystrophin with AAV$163,516
R21 · FY2008 · NS · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$276,863
R01 · FY2007 · AR · contact PI
Novel hybrid AAV vectors for cystic fibrosis gene therapy$181,749
R21 · FY2007 · DK · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$285,132
R01 · FY2006 · AR · contact PI
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$316,463
R01 · FY2005 · AR
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$316,463
R01 · FY2004 · AR
Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy$316,463
R01 · FY2003 · AR